Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 7/20 | 0.77 |
| ▸ | NPC1 | O15118 | 5/20 | 0.77 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.77 |
| ▸ | MAPT | P10636 | 7/20 | 0.74 |
| ▸ | PKM | P14618 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.72 |
| ▸ | MEN1 | O00255 | 3/20 | 0.72 |
| ▸ | ESRRG | P62508 | 5/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.70 |
| ▸ | GAA | P10253 | 3/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.70 |
| ▸ | POLB | P06746 | 1/20 | 0.70 |
| ▸ | NR4A1 | P22736 | 1/20 | 0.70 |
| ▸ | BLM | P54132 | 1/20 | 0.70 |
| ▸ | ESR1 | P03372 | 1/20 | 0.69 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.69 |
| ▸ | LMNA | P02545 | 2/20 | 0.68 |
| ▸ | GFER | P55789 | 2/20 | 0.68 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.68 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1563347 | 1.00 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL6634765 | 1.00 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL1129157 | 0.93 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL8253424 | 0.93 | RAB9A (0.77) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL6720187 | 0.93 | RAB9A (0.87) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL19283313 | 0.91 | ESRRG (0.79) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL19283311 | 0.91 | ESRRG (0.79) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL2830919 | 0.90 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL711754 | 0.90 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2MAPTPKM | |
| SCHEMBL711755 | 0.90 | RAB9A (0.81) | RAB9ANPC1SMN1; SMN2MAPTPKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12552782-B2 | Analogs of nitrofuran antibiotics to combat resistance | THE TRUSTEES OF INDIANA UNIVERSITY (US) | 2026-02-17 | — | — | US | disclosed |
| US-20250319056-A1 | METHODS FOR TREATING CANCER | UNIV INDIANA TRUSTEES (US) | 2025-10-16 | — | — | US | disclosed |
| US-20230295136-A1 | Analogs of Nitrofuran Antibiotics to Combat Resistance | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA | 2023-09-21 | — | — | US | disclosed |
| US-20220009914-A1 | Analogs of Nitrofuran Antibiotics to Combat Resistance | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-01-13 | — | — | US | disclosed |
| US-9556351-B2 | Rubber composition suitable for use as a cap ply in a tire | Bridgestone Americas Tire Operations, Inc. (US) | 2017-01-31 | — | — | US | disclosed |
| US-20160040024-A1 | RUBBER COMPOSITION SUITABLE FOR USE AS A CAP PLY IN A TIRE | BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC | 2016-02-11 | — | — | US | disclosed |
| US-9163127-B2 | Rubber composition suitable for use as a cap ply in a tire | BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) | 2015-10-20 | — | — | US | disclosed |
| US-20140005320-A1 | RUBBER COMPOSITION SUITABLE FOR USE AS A CAP PLY IN A TIRE | BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) | 2014-01-02 | — | — | US | disclosed |
| EP-2665771-A2 | A RUBBER COMPOSITION SUITABLE FOR USE AS A CAP PLY IN A TIRE | Bridgestone Americas Tire Operations, LLC (US) | 2013-11-27 | — | — | EP | disclosed |
| WO-2012099955-A2 | A RUBBER COMPOSITION SUITABLE FOR USE AS A CAP PLY IN A TIRE | BRIDGESTONE AMERICAS TIRE OPERATIONS, LLC (US) | 2012-07-26 | — | — | WO | disclosed |
| EP-0909788-B1 | RUBBER COMPOSITION AND PNEUMATIC TIRES | BRIDGESTONE CORP (JP) | 2004-12-01 | — | — | EP | disclosed |
| US-6822027-B2 | MODIFIED STYRENE-BUTADIENE COPOLYMER RUBBER THAT HAS A TIN ATOM, NATURAL RUBBER OR SYNTHETIC ISOPRENE RUBBERS, AND A HYDRAZIDE COMPOUND. | BRIDGESTONE CORPORATION (JP) | 2004-11-23 | — | — | US | disclosed |
| EP-1475408-A1 | RUBBER COMPOSITION AND PNEUMATIC TIRE MADE THEREFROM | Bridgestone Corporation (JP) | 2004-11-10 | — | — | EP | disclosed |
| EP-1420044-A2 | Rubber composition and pneumatic tire | Bridgestone Corporation (JP) | 2004-05-19 | — | — | EP | disclosed |
| US-6506849-B1 | Natural or synthetic rubber; maleimide compound; and polyaniline, hydrazide and/or amine compound; workability, elasticity | BRIDGESTONE CORPORATION (JP) | 2003-01-14 | — | — | US | disclosed |
| US-6380288-B1 | LOW HEAT GENERATION PROPERTY, AGING REISTANCE, ALSO FOR PRODUCING VIBRATION ISOLATORS, BELTS AND HOSES AS WELL AS TIRE MATERIALS SUCH AS TIRE TREADS, UNDERTREADS, CARCASSES, SIDE WALLS AND BEADS | BRIDGESTONE CORPORATION | 2002-04-30 | — | — | US | disclosed |
| US-20020049294-A1 | Rubber composition and heavy duty pneumatic tire using the rubber composition | BRIDGESTONE CORPORATION | 2002-04-25 | — | — | US | disclosed |
| EP-1184412-A1 | Rubber composition and heavy duty pneumetic tire using the rubber composition | Bridgestone Corporation (JP) | 2002-03-06 | — | — | EP | disclosed |
| EP-1083199-A1 | RUBBER COMPOSITION AND PNEUMATIC TIRE | BRIDGESTONE CORPORATION (JP) | 2001-03-14 | — | — | EP | disclosed |
| EP-0909788-A1 | RUBBER COMPOSITION AND PNEUMATIC TIRES | Bridgestone Corporation (JP) | 1999-04-21 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295136-A1 | Analogs of Nitrofuran Antibiotics to Combat Resistance | ATF4, ATF1, FBL | RAB9A 3191/4885NPC1 1389/4885SMN1; SMN2 3306/4885 |
| US-12552782-B2 | Analogs of nitrofuran antibiotics to combat resistance | CDC37, NRDC, SEC63 | RAB9A 1925/4885NPC1 273/4885SMN1; SMN2 1678/4885 |
| US-20250319056-A1 | METHODS FOR TREATING CANCER | HSP90AB1, HSP90B1, HSP90AB2P | RAB9A 3393/4885NPC1 577/4885SMN1; SMN2 1352/4885 |
| US-20220009914-A1 | Analogs of Nitrofuran Antibiotics to Combat Resistance | ATF4, ATF1, FBL | RAB9A 3191/4885NPC1 1389/4885SMN1; SMN2 3306/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.